Abivax S.A. (ABVX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $105.91, ABVX has negative trailing earnings (P/E not meaningful) and an ROE of -73.87%. Market capitalisation stands at $7.8B.
Balance sheet quality for ABVX: current ratio of 8.7, net cash position of $484.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $105.91 |
| Market Cap | $7.8B |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | 15.11 |
| EV / EBITDA | -24.97 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -73.87% |
| Return on Invested Capital | -44.70% |
| Return on Assets | -57.54% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 8.75 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 34.93 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.2B | 29.72 | -56.6% | |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | |||
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
Price Performance
| 1 month | -11.04% |
| 3 months | +6.72% |
| Year-to-date | -21.54% |
| 1 year | +30.63% |
52-Week Range
| 52-week High | $148.83 |
| 52-week Low | $69.81 |
| Avg Volume (90d) | 1.7M |
Related companies: AXSM · CORT · CYTK · HALO · JAZZ · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks